Endocrine treatments include GnRH agonists (leuprolide 3.75 mg monthly) for central precocious puberty (Song et al., 2022), zoledronate for hypercalcemia (Tise et al., 2022), and thyroxine for hypothyroidism (Hunter, 2002). Here, GNRH1 is linked to hypercalcemia disease.